Oral Treatment for African Trypanosoma brucei gambiense Trypanosomiasis

Oral fexinidazole was effective in 91% of late-stage cases in a phase II/III trial.

Many cases of African trypanosomiasis caused by Trypanosoma brucei gambiense (g-HAT) occur in remote and limited-resource areas. Currently the recommended treatment for late-stage (meningoencephalitic) infection requires intravenous medication in a hospital setting. Investigators now report results of a multicenter, randomized, phase II/III open-label noninferiority trial of oral fexinidazole versus nifurtimox–eflornithine combination in patients aged ≥15 years with late-stage g-HAT. Patients hospitalized at g-HAT treatment centers in the Democratic Republic of Congo (9 centers) and Central African Republic (1 center) were randomized 2:1 to receive oral fexinidazole for 10 days or oral nifurtimox for 10 days plus eflornithine infusions for …

Reviewing Author

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Mary E. Wilson, MD

Disclosures

Consultant/Advisory BoardOneHealthTrust (formerly Center for Disease Dynamics, Economics, and Policy); Global Health Institute, University of Wisconsin

RoyaltiesUpToDate

Editorial BoardsJournal of Travel Medicine

Oral Treatment for African Trypanosoma brucei gambiense Trypanosomiasis

Topics

Reviewing Author